Patients
HCC,, HCV, hepatitis C, tumor, extrahepatic metastases, BCLC, hepatocellular carcinoma, HCC, macrovascular invasion
HEPATITIS B, VIRUS, TUMOR, ONCOLOGY, LIVER CANCER
Between 7 July 2020 and 4 August 2021, 59 patients were enrolled (cohort A, Diagram of patient disposition.Baseline demographics and clinical characteristics.Data are No. (%) unless otherwise indicated.AFP, alpha-fetoprotein; BCLC, Barcelona Clinic Liver Cancer; ECOG, Eastern Cooperative Oncology Group; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; TC, tumor cell; IC, immune cell.Median age was 56.3 (range: 24–72) years; 81.4% of subjects were men; 52.5% and 47.5% of subjects had ECOG PS of 0 and 1, respectively. Child-Pugh scores of A5 and A6 were reported for 83.1% and 16.9% of cases, respectively. Most of the HCC patients were HBV-related, accounting for 91.5% of subjects. BCLC stage B was noted in 35.6% of subjects and stage C was noted in 64.4%. There are 54.2% of patients who had extrahepatic metastases, and 10.2% of patients had macrovascular invasion; 27.1% of patients had an alpha fetoprotein level ≥400 μg/L.